Filtered By:
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 7677 results found since Jan 2013.
Harnessing Dendritic Cells: Next Frontier for Durable Immune Control in Myeloma
Clin Cancer Res. 2023 Sep 22:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-2292. Online ahead of print.ABSTRACTImmune-based approaches including T-cell redirection have transformed the therapeutic landscape in myeloma. Injection of dendritic cells (DC) led to the induction of immune responses in vaccinated patients with myeloma. These studies pave the way for future combination strategies harnessing DCs to enhance tumor immunity and improve outcomes in myeloma. See related article by Freeman et al., p. 000.PMID:37737650 | DOI:10.1158/1078-0432.CCR-23-2292
Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Madhav V Dhodapkar Source Type: research
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
CONCLUSIONS: Two doses of DC:Ad-S, one given immediately before and another after ASCT, were feasible and safe. A high frequency of vaccine-specific immune responses was seen in combination with durable clinical outcomes, supporting ongoing investigation into the potential of this approach.PMID:37735756 | DOI:10.1158/1078-0432.CCR-22-3987
Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Ciara L Freeman Reginald Atkins Indumathy Varadarajan Meghan Menges Jeffrey Edelman Rachid Baz Jason Brayer Omar Castaneda Puglianini Jose Leonel Ochoa-Bayona Taiga Nishihori Kenneth H Shain Bijal Shah Dung Tsa Chen Linda Kelley Domenico Coppola Melissa A Source Type: research
Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets
CONCLUSION: This review summarises important predictive ncRNA biomarkers that were reported in cancer patients treated with different immunotherapeutic modalities, including monoclonal antibodies, small molecule inhibitors, cancer vaccines and CAR-T cells. In addition, a concise discussion on forthcoming perspectives is provided, outlining technical approaches for the optimal utilisation of immunomodulatory ncRNA biomarkers as predictive tools and therapeutic targets.PMID:37735815 | DOI:10.1002/ctm2.1425
Source: Clinical Lung Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Murad Alahdal Eyad Elkord Source Type: research
Regulatory circuits of mitophagy restrict distinct modes of cell death during memory CD8 < sup > + < /sup > T cell formation
Sci Immunol. 2023 Sep 29;8(87):eadf7579. doi: 10.1126/sciimmunol.adf7579. Epub 2023 Sep 22.ABSTRACTMitophagy, a central process guarding mitochondrial quality, is commonly impaired in human diseases such as Parkinson's disease, but its impact in adaptive immunity remains unclear. The differentiation and survival of memory CD8+ T cells rely on oxidative metabolism, a process that requires robust mitochondrial quality control. Here, we found that Parkinson's disease patients have a reduced frequency of CD8+ memory T cells compared with healthy donors and failed to form memory T cells upon vaccination against COVID-19, highli...
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Fabien Franco Alessio Bevilacqua Ruey-Mei Wu Kung-Chi Kao Chun-Pu Lin Lor ène Rousseau Fu-Ti Peng Yu-Ming Chuang Jhan-Jie Peng Jaeoh Park Yingxi Xu Antonino Cassotta Yi-Ru Yu Daniel E Speiser Federica Sallusto Ping-Chih Ho Source Type: research
Harnessing Dendritic Cells: Next Frontier for Durable Immune Control in Myeloma
Clin Cancer Res. 2023 Sep 22:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-2292. Online ahead of print.ABSTRACTImmune-based approaches including T-cell redirection have transformed the therapeutic landscape in myeloma. Injection of dendritic cells (DC) led to the induction of immune responses in vaccinated patients with myeloma. These studies pave the way for future combination strategies harnessing DCs to enhance tumor immunity and improve outcomes in myeloma. See related article by Freeman et al., p. 000.PMID:37737650 | DOI:10.1158/1078-0432.CCR-23-2292
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Madhav V Dhodapkar Source Type: research
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
CONCLUSIONS: Two doses of DC:Ad-S, one given immediately before and another after ASCT, were feasible and safe. A high frequency of vaccine-specific immune responses was seen in combination with durable clinical outcomes, supporting ongoing investigation into the potential of this approach.PMID:37735756 | DOI:10.1158/1078-0432.CCR-22-3987
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Ciara L Freeman Reginald Atkins Indumathy Varadarajan Meghan Menges Jeffrey Edelman Rachid Baz Jason Brayer Omar Castaneda Puglianini Jose Leonel Ochoa-Bayona Taiga Nishihori Kenneth H Shain Bijal Shah Dung Tsa Chen Linda Kelley Domenico Coppola Melissa A Source Type: research
A H3K27M-targeted vaccine in adults with diffuse midline glioma
Nat Med. 2023 Sep 21. doi: 10.1038/s41591-023-02555-6. Online ahead of print.ABSTRACTSubstitution of lysine 27 to methionine in histone H3 (H3K27M) defines an aggressive subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide vaccine (H3K27M-vac) induces mutation-specific immune responses that control H3K27M+ tumors in major histocompatibility complex-humanized mice. Here we describe a first-in-human treatment with H3K27M-vac of eight adult patients with progressive H3K27M+ diffuse midline glioma on a compassionate use basis. Five patients received H3K27M-vac combined with anti-PD-1 treat...
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Niklas Grassl Isabel Poschke Katharina Lindner Lukas Bunse Iris Mildenberger Tamara Boschert Kristine J ähne Edward W Green Ingrid H ülsmeyer Simone J ünger Tobias Kessler Abigail K Suwala Philipp Eisele Michael O Breckwoldt Peter Vajkoczy Oliver M Gra Source Type: research
Harnessing Dendritic Cells: Next Frontier for Durable Immune Control in Myeloma
Clin Cancer Res. 2023 Sep 22:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-2292. Online ahead of print.ABSTRACTImmune-based approaches including T-cell redirection have transformed the therapeutic landscape in myeloma. Injection of dendritic cells (DC) led to the induction of immune responses in vaccinated patients with myeloma. These studies pave the way for future combination strategies harnessing DCs to enhance tumor immunity and improve outcomes in myeloma. See related article by Freeman et al., p. 000.PMID:37737650 | DOI:10.1158/1078-0432.CCR-23-2292
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Madhav V Dhodapkar Source Type: research
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
CONCLUSIONS: Two doses of DC:Ad-S, one given immediately before and another after ASCT, were feasible and safe. A high frequency of vaccine-specific immune responses was seen in combination with durable clinical outcomes, supporting ongoing investigation into the potential of this approach.PMID:37735756 | DOI:10.1158/1078-0432.CCR-22-3987
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Ciara L Freeman Reginald Atkins Indumathy Varadarajan Meghan Menges Jeffrey Edelman Rachid Baz Jason Brayer Omar Castaneda Puglianini Jose Leonel Ochoa-Bayona Taiga Nishihori Kenneth H Shain Bijal Shah Dung Tsa Chen Linda Kelley Domenico Coppola Melissa A Source Type: research
Personalized Medicine's Coming of Age: One Drug, One Patient
Clin Cancer Res. 2023 Sep 21. doi: 10.1158/1078-0432.CCR-23-2194. Online ahead of print.ABSTRACTA dendritic cell/myeloma fusion vaccine, given with lenalidomide and GM-CSF, did not result in a statistically significant increase in CR rates at 1-year post-transplant but was associated with a significant increase in circulating multiple myeloma-reactive lymphocytes indicative of tumor-specific immunity.PMID:37733765 | DOI:10.1158/1078-0432.CCR-23-2194
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Muzaffar H Qazilbash Larry W Kwak Source Type: research
Chronic Respiratory Diseases as a Risk Factor for Herpes Zoster Infection
CONCLUSIONS: In a standard clinical practice setting, the most prevalent respiratory diseases (asthma, COPD and lung cancer) are related to a higher risk of HZ and PHN. These data are fundamental to assess the potential impact of vaccination in this population.PMID:37734964 | DOI:10.1016/j.arbres.2023.08.010
Source: Archivos de Bronconeumologia - September 21, 2023 Category: Respiratory Medicine Authors: Diego Morena Sara Lumbreras Jos é Miguel RodrÃguez Carolina Campos Mar Ãa Castillo Mar Ãa Benavent Jos é Luis Izquierdo Source Type: research
Identification of γ-Fagarine as a novel antiviral agent against respiratory virus (hMPV) infection
In this study, we aim to investigate the effect of γ-Fagarine on hMPV infection and explore its underlying molecular mechanisms. Vero-E6 and 16HBE cells were used as cell models. Virus replication and microcosm character were explored in Vero-E6 cells. Then, the antiviral activities were investigated by quantitative real-time PCR (RT-qPCR), western blotting (WB), and indirect immunofluorescence assays (IFAs) in Vero-E6 and 16HBE. Potential mechanisms of γ-Fagarine related to HSPG and lysosome pH were assessed in 16HBE cells. Lastly, a virus-infected mouse model was established and antiviral assay in vivo was conducted. Î...
Source: Virus Research - September 21, 2023 Category: Virology Authors: Jinhua Li Yao Zhao Ying Dai Junning Zhao Source Type: research
Personalized Medicine's Coming of Age: One Drug, One Patient
Clin Cancer Res. 2023 Sep 21. doi: 10.1158/1078-0432.CCR-23-2194. Online ahead of print.ABSTRACTA dendritic cell/myeloma fusion vaccine, given with lenalidomide and GM-CSF, did not result in a statistically significant increase in CR rates at 1-year post-transplant but was associated with a significant increase in circulating multiple myeloma-reactive lymphocytes indicative of tumor-specific immunity.PMID:37733765 | DOI:10.1158/1078-0432.CCR-23-2194
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Muzaffar H Qazilbash Larry W Kwak Source Type: research
